Ofer Goldberg - Clal Biotechnology VP
| CBI Stock | 46.40 1.60 3.57% |
VP
Mr. Ofer Goldberg serves as Vice President at Clal Biotechnology Industries Ltd. since September 1, 2003. Previously, Mr. Goldberg served as Director for BioCancell Therapeutics Inc from May 17, 2007 to October 21, 2009 since 2003.
| Age | 45 |
| Tenure | 21 years |
| Phone | 972 3 612 1616 |
| Web | https://www.cbi.co.il |
Clal Biotechnology Management Efficiency
The company has return on total asset (ROA) of (0.1194) % which means that it has lost $0.1194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4545) %, meaning that it generated substantial loss on money invested by shareholders. Clal Biotechnology's management efficiency ratios could be used to measure how well Clal Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | VP Age | ||
| John Hunter | Compugen | 52 | |
Management Performance
| Return On Equity | -0.45 | |||
| Return On Asset | -0.12 |
Clal Biotechnology Leadership Team
Elected by the shareholders, the Clal Biotechnology's board of directors comprises two types of representatives: Clal Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clal. The board's role is to monitor Clal Biotechnology's management team and ensure that shareholders' interests are well served. Clal Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clal Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ofer Goldberg, VP | ||
| Iris Sadeh, Accountant | ||
| Liat Nissan, Controller | ||
| Sigalia Heifetz, Director | ||
| Shmuel Rubinstein, External Director | ||
| Tomer Babai, Director | ||
| Dafna Gruber, Director | ||
| Aharon Schwartz, Director | ||
| Gavriel Barabash, Director | ||
| Isaac Kohlberg, Director | ||
| Nofar Malovani, Director | ||
| Arnon MD, Medical Director | ||
| Pr MD, VP MediWound | ||
| Assaf Segal, Acting Officer | ||
| Ofer Gonen, Vice President | ||
| Avraham Fischer, Chairman of the Board | ||
| Yuval Yanai, External Director | ||
| Julian Adams, President Chief Scientific Officer | ||
| Orit Lidor, VP and General Counsel | ||
| Shiran Manor, Co Sec | ||
| Etty Kliger, VP MediWound |
Clal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clal Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | |||
| Return On Asset | -0.12 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (0.86) % | |||
| Current Valuation | 89.12 M | |||
| Shares Outstanding | 156.85 M | |||
| Shares Owned By Insiders | 64.58 % | |||
| Price To Earning | (218.28) X | |||
| Price To Book | 0.68 X | |||
| Price To Sales | 2.79 X |
Pair Trading with Clal Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Clal Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Clal Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving against Clal Stock
| 0.62 | FVT | Ai Conversation Systems | PairCorr |
The ability to find closely correlated positions to Clal Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Clal Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Clal Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Clal Biotechnology Industries to buy it.
The correlation of Clal Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Clal Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Clal Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Clal Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clal Biotechnology Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Clal Stock analysis
When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |